Millennium Management’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-534,054
| Closed | -$6.99M | – | 5698 |
|
|
2025
Q4 | $6.99M | Sell |
534,054
-2,500,473
| -82% | -$29.9M | ﹤0.01% | 2650 |
|
|
2025
Q3 | $22.1M | Buy |
3,034,527
+64,800
| +2% | +$439K | 0.01% | 1563 |
|
|
2025
Q2 | $15.9M | Buy |
2,969,727
+1,335,572
| +82% | +$6.47M | 0.01% | 1811 |
|
|
2025
Q1 | $8.73M | Sell |
1,634,155
-290,348
| -15% | -$2.03M | ﹤0.01% | 2328 |
|
|
2024
Q4 | $17.2M | Sell |
1,924,503
-561,683
| -23% | -$5.97M | 0.01% | 1647 |
|
|
2024
Q3 | $27.4M | Buy |
2,486,186
+644,123
| +35% | +$7.16M | 0.01% | 1279 |
|
|
2024
Q2 | $16.8M | Buy |
1,842,063
+174,318
| +10% | +$1.7M | 0.01% | 1647 |
|
|
2024
Q1 | $23.5M | Buy |
1,667,745
+1,447,611
| +658% | +$18M | 0.01% | 1438 |
|
|
2023
Q4 | $1.69M | Buy |
+220,134
| New | +$1.22M | ﹤0.01% | 3742 |
|
|
2023
Q3 | – | Sell |
-276,672
| Closed | -$2.3M | – | 6102 |
|
|
2023
Q2 | $2.3M | Sell |
276,672
-17,420
| -6% | -$201K | ﹤0.01% | 3350 |
|
|
2023
Q1 | $3.91M | Buy |
294,092
+175,466
| +148% | +$2.37M | ﹤0.01% | 2824 |
|
|
2022
Q4 | $1.77M | Buy |
118,626
+97,916
| +473% | +$1.01M | ﹤0.01% | 3661 |
|
|
2022
Q3 | $187K | Buy |
20,710
+3,793
| +22% | +$25.4K | ﹤0.01% | 5693 |
|
|
2022
Q2 | $51K | Buy |
+16,917
| New | +$75.8K | ﹤0.01% | 6199 |
|
|
2022
Q1 | – | Sell |
-10,259
| Closed | -$55K | – | 6885 |
|
|
2021
Q4 | $55K | Buy |
+10,259
| New | +$67.5K | ﹤0.01% | 6450 |
|
|
2021
Q3 | – | Sell |
-76,935
| Closed | -$974K | – | 6766 |
|
|
2021
Q2 | $974K | Buy |
+76,935
| New | +$999K | ﹤0.01% | 4689 |
|
|
2021
Q1 | – | Sell |
-9,516
| Closed | -$122K | – | 5895 |
|
|
2020
Q4 | $122K | Buy |
9,516
+7,420
| +354% | +$132K | ﹤0.01% | 4986 |
|
|
2020
Q3 | $78 | Sell |
2,096
-675
| -24% | -$26.7K | ﹤0.01% | 4255 |
|
|
2020
Q2 | $107K | Buy |
+2,771
| New | +$98.7K | ﹤0.01% | 3972 |
|
|
2019
Q3 | – | Sell |
-3,520
| Closed | -$170K | – | 4147 |
|
|
2019
Q2 | $170K | Sell |
3,520
-8,534
| -71% | -$387K | ﹤0.01% | 3798 |
|
|
2019
Q1 | $573K | Buy |
+12,054
| New | +$409K | ﹤0.01% | 3186 |
|
|
2018
Q4 | – | Sell |
-1,379
| Closed | -$66K | – | 3735 |
|
|
2018
Q3 | $66K | Sell |
1,379
-7,457
| -84% | -$335K | ﹤0.01% | 3783 |
|
|
2018
Q2 | $508K | Buy |
+8,836
| New | +$815K | ﹤0.01% | 3157 |
|
|
2017
Q4 | – | Sell |
-272
| Closed | -$35K | – | 3774 |
|
|
2017
Q3 | $35K | Buy |
+272
| New | +$22.7K | ﹤0.01% | 3427 |
|
|
2016
Q1 | – | Sell |
-431
| Closed | -$205K | – | 3252 |
|
|
2015
Q4 | $205K | Sell |
431
-635
| -60% | -$305K | ﹤0.01% | 3077 |
|
|
2015
Q3 | $517K | Sell |
1,066
-181
| -15% | -$129K | ﹤0.01% | 2640 |
|
|
2015
Q2 | $913K | Buy |
+1,247
| New | +$943K | ﹤0.01% | 2332 |
|
Millennium Management's ATXS Position: Q1 2026 in Review
Millennium Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 534,054 shares — an estimated $6.99M sold.
Millennium Management first reported a position in ATXS in Q2 2015 and held it in 27 quarters. The position peaked at $27.4M in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Millennium Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Millennium Management sold 534,054 Astria Therapeutics shares in Q1 2026, an estimated $6.99M.
- Millennium Management first reported a position in Astria Therapeutics in Q2 2015 and held it in 27 quarters.
- Millennium Management's Astria Therapeutics position peaked at $27.4M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.